.svg)
Commercial rebates paid to private payers under mutually agreed-upon contracts make up a significant portion of the price concessions that manufacturers give on their drugs. Though this arrangement enables manufacturers to make their drugs more widely available to patients, challenges may arise when identifying exclusions. Even when ineligible rebates are clearly defined in commercial contracts, it can be tough to identify them because of overlap with 340B.
Company W approached Kalderos with an ongoing goal of mitigating waste in drug costs. Using a combination of its Drug Discount Management platform and Commercial Discount Monitoring solution, Kalderos identified more than $45 million in commercial exclusions for Company W over four years. Furthermore, Company W continues to glean actionable insights from the data surfaced by the solution that it can use to improve its contract negotiation strategy.
Read our impact study to learn more about Kalderos’ approach to addressing ineligible rebates in the commercial sphere.
